Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01810250
Other study ID # EAGLE Registry
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 2012
Est. completion date May 2023

Study information

Verified date December 2023
Source Catharina Ziekenhuis Eindhoven
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The Department of Vascular Surgery at Catharina Hospital Eindhoven, The Netherlands initiates the Endurant for Challenging Anatomy: Global Experience (EAGLE) Registry. The aim of this study is to collect clinical information on the performance of the Endurant Stent Graft System for endovascular repair in anatomically challenging aneurysms, and to critically assess whether the current guidelines for anatomic eligibility to endovascular treatment with this system are still applicable. This study aims at creating a database that can be pooled/ compared with the ENGAGE database. This study aims at answering two major questions: 1. Is the technical success rate of successful delivery and deployment of the Endurant (II) similar in anatomically challenging aneurysm? 2. Is the successful treatment rate comparable in anatomically challenging aneurysms, or does treatment of these aneurysms lead to more complications and reinterventions?


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date May 2023
Est. primary completion date January 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years or minimum age as required by local regulations - Indication for elective EVAR - Challenging AAA anatomy - Intention to electively implant the Endurant or Endurant II Stent Graft System© - Signed informed consent form Exclusion Criteria: - Subjects with intolerance to contrast media - Chimneys or fenestrated device procedures - High probability of non-adherence to physician's follow-up requirements - Current participation in a concurrent trial that may confound study results

Study Design


Intervention

Device:
Endurant Stent Graft


Locations

Country Name City State
Netherlands Catharina Ziekenhuis Eindhoven Noord-Brabant

Sponsors (1)

Lead Sponsor Collaborator
Catharina Ziekenhuis Eindhoven

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical success Freedom from:
Increase of AAA diameter > 5 mm (1 month measurement as baseline)
Type I&III endoleaks
Aneurysm rupture
Conversion to surgery
Stent graft migration (>10mm) resulting in SAE or reintervention
Stent graft occlusion
12 months
Secondary Helath Related Quality of Life Scores EQ-5D VAS EQ-5D index 12 months